Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-Current Deffered Revenue (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Non-Current Deffered Revenue for 11 consecutive years, with $12.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 44.53% to $12.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.5 million, a 44.53% decrease, with the full-year FY2024 number at $18.3 million, down 53.01% from a year prior.
  • Non-Current Deffered Revenue was $12.5 million for Q3 2025 at Intellia Therapeutics, roughly flat from $12.5 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $63.5 million in Q4 2021 to a low of $12.5 million in Q2 2025.
  • A 5-year average of $29.6 million and a median of $25.7 million in 2022 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 251.99% in 2021, then crashed 71.99% in 2023.
  • Intellia Therapeutics' Non-Current Deffered Revenue stood at $63.5 million in 2021, then plummeted by 68.6% to $19.9 million in 2022, then soared by 94.93% to $38.9 million in 2023, then crashed by 53.01% to $18.3 million in 2024, then plummeted by 31.32% to $12.5 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Non-Current Deffered Revenue are $12.5 million (Q3 2025), $12.5 million (Q2 2025), and $13.2 million (Q1 2025).